Insmed had its Relative Strength (RS) Rating upgraded from 90 to 93 Thursday.
Here Are 3 Keys For Successful Stock Investing
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves.
Insmed has moved more than 5% past an 84.91 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Insmed reported 0% EPS growth last quarter. Sales gains came in at 23%.
Insmed earns the No. 127 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
